

## CLARIFICATION AND CORRECTION OF REMARKS

The remarks provide with the response filed on January 18, 2008, incorrectly described the passage at page 3, lines 10-15 of the present application. To correct this error, Applicants provide below a corrected version of the last paragraph of the remarks. The last paragraph of the remarks should read as follows:

Applicants respectfully traverse the Office characterization of the special technical feature of the Groups: the special technical feature of the Groups is a composition comprising a therapeutic agent which inhibits a Rho GTPase, and a neuronal cell targeting component comprising an Hc domain of botulinum C1 toxin, **wherein the Hc domain has been made recombinantly**. This distinction is very significant: Shone *et al.* discuss botulinum C1 toxin as a targeting neurotoxin, not the Hc domain of botulinum C1 toxin made recombinantly. Furthermore, as noted on page 3, lines 10-15, of the present application, the Hc domain of some botulinum toxins made recombinantly have significantly reduced affinity and specificity for neuronal cells, as compared to those same structures not produced recombinantly. Therefore, the Hc domain of botulinum C1 toxin made recombinantly is distinct from botulinum C1 toxin described by Shone *et al.* Applicants submit that the claims do have the same or corresponding special technical feature. Withdrawal of the Restriction Requirement is respectfully requested.

Respectfully submitted,



Paul E. Rauch, Ph.D.  
Registration No. 38,591

Evan Law Group LLC  
600 West Jackson  
Suite 625  
Chicago, Illinois 60661  
(312) 876-1400